Today between 60 and 70 percent of medical decisions are achieved as a result of diagnostic testing, yet only 1 percent of funds allocated to healthcare around the world are spent on such testing. In the pursuit of more cost effective and personalized medicine, diagnostics testing will continue to play a critical role in providing the necessary information for healthcare professionals to deliver the right care to the right patient in an efficient manner.
At the forefront, Indiana companies and researchers alike are developing cutting-edge technologies in diabetes and oncology that will significantly impact the way we diagnose and treat patients. In this session, we’ll learn about interesting new diagnostic testing technologies and how they will have an impact on antibiotic stewardship, delivering results at the point of care, and managing challenges in oncology. Three speakers will engage the audience with a question and answer session following brief presentations:
- John Osiecki, Director of Medical and Scientific Affairs, Molecular Diagnostics, Roche Diagnostics Corporation
- Corinne Fantz, Director of Medical and Scientific Affairs, Point of Care, Roche Diagnostic Corporation
- Sarah Moseley, Lead Scientific Affairs Manager, Medical and Scientific Affairs, Molecular Diagnostics, Roche Diagnostics Corporation